STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-07-26
Here’s whether Exelixis Inc (EXEL) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.63% over 10 days); RSI 49 — healthy momentum range; strong 1-year return of +23.6%; 3-month momentum positive (+23.2%). Concerns: declining volume on rally — weak conviction (0.79x 30d avg). Currently 3.8% off its 52-week high. Score: +6/7.
EXEL is in a confirmed uptrend, trading above both its 50-day ($53.05) and 200-day ($45.37) moving averages. An RSI of 49.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +23.6% compares to +16.5% for SPY (beat the market by 7.2%).
$10,000 invested 1 year ago→ $12,362 today
vs. S&P 500 (SPY) — same period beat market by 7.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($45.37)
✓Above 50-day MA ($53.05)
✓RSI(14) neutral zone (30–70) — currently 49.1
✓Positive return (+23.6%)
✓Within 10% of period high (−3.8%)
Period Range $55.37
$33.76$57.57
RSI (14) 49.1
0 · OversoldOverbought · 100
Key Metrics
Price$55.37
Period Return+23.6%
Period High$57.57
Period Low$33.76
Drawdown−3.8%
MA-50$53.05
MA-200$45.37
RSI (14)49.1
Avg Volume (30d)2.6M
vs. SPYbeat by 7.2%
Return Rank#331 of 999
Trend Signals
Price is above the 200-day moving average ($45.37)